CHI3L1 and in situ carcinoma: Despite its not entirely understood biological function, based on the available evidence, YKL-40 is commonly regarded as a potential biomarker of MS activity and conversion from CIS to clinically definite multiple sclerosis [24], which is in line with the modulatory role of astrocytes in the disease [25].